SUPN continues to be a big winner. Just look at the prescription growth in the last three years. With this indication now added on label, continued growth is ahead. SUPN customers require long term drug therapy. Investors can't ask for a better situation. The pipeline continues to look good, too.
Market Data 
Markets 
AI
